[go: up one dir, main page]

WO2024240864A1 - Matériau réticulé comprenant des fractions polysaccharidiques interconnectées par des liaisons ester - Google Patents

Matériau réticulé comprenant des fractions polysaccharidiques interconnectées par des liaisons ester Download PDF

Info

Publication number
WO2024240864A1
WO2024240864A1 PCT/EP2024/064195 EP2024064195W WO2024240864A1 WO 2024240864 A1 WO2024240864 A1 WO 2024240864A1 EP 2024064195 W EP2024064195 W EP 2024064195W WO 2024240864 A1 WO2024240864 A1 WO 2024240864A1
Authority
WO
WIPO (PCT)
Prior art keywords
cross
moieties
linked material
polysaccharide
polysaccharide moieties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/064195
Other languages
English (en)
Inventor
Cleiton KUNZLER
Colin DRABE
Radovan VUKICEVIC
Radia El-Banna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Aesthetics GmbH
Original Assignee
Merz Aesthetics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Aesthetics GmbH filed Critical Merz Aesthetics GmbH
Priority to AU2024277576A priority Critical patent/AU2024277576A1/en
Publication of WO2024240864A1 publication Critical patent/WO2024240864A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Definitions

  • Cross-linked material comprising polysaccharide moieties interconnected by ester bonds
  • the present invention relates to a method for preparing a cross-linked material, comprising reaction of at least some carboxylic acid residues of polysaccharide moieties with at least some hydroxy residues of polysaccharide moieties to form ester bonds cross-linking polysaccharide moieties covalently with each other, wherein the reaction is triggered by one or more triazine-based activating agents.
  • the invention refers to a cross-linked material obtainable from such method, compositions comprising such, and uses thereof.
  • Facial and body re-shaping is of increasing interest. For example, filling of wrinkles of face and/or body, rejuvenation of the skin, breast reconstruction or augmentation, or soft-tissue augmentation of other kind is regularly of interest.
  • soft-tissue fillers that can be injected subcutaneously or within the deeper layers of the skin have been developed or are under development.
  • Soft-tissue fillers are typically gels such as hydrogels.
  • fillers should remain in a spatially defined area and have a sufficient stability in biological systems such as when being injected.
  • Suitable materials used for soft-tissue filling in the art are polysaccharides such as, e.g., hyaluronic acid (HA). Many polysaccharides such as hyaluronic acids have good biological acceptability. However, one significant drawback is that biodegradation of such material based on polysaccharides such as hyaluronic acid is comparably rapid and the filler material is not suitable for long-term solutions. It has limited longevity in subjects administered therewith, often of less than a desired minimum range of several months. When such polysaccharide is degraded rapidly in the body, the viscosity decreases undesirably rapidly and the filling effect is not sufficiently long lasting.
  • HA hyaluronic acid
  • cross-link polysaccharides such as hyaluronic acid with synthetic xenobiotic cross-linking agents such as, for example, the epoxide-based linker butanediol diglycidyl ether (BDDE) as for instance described in US-A 2012/0190644, WO 2015/149941 or WO 2020/030629, or di- or multinucleophilic functional cross-linkers such as described in US-A 2020/0140626.
  • BDDE epoxide-based linker butanediol diglycidyl ether
  • di- or multinucleophilic functional cross-linkers such as described in US-A 2020/0140626.
  • Such material have several drawbacks. For instance, residuals of such non-reacted or half-reacted bivalent linkers can be harmful and limit usability of the materials.
  • cross-linking with proteins, peptides and amino acids has been considered.
  • polysaccharides such as hyaluronic acid with cross-linking proteins.
  • hyaluronic acid was cross-linked with elastin as described in WO 2011/119468.
  • polysaccharides were also cross-linked with fibroin such as described in WO 2022/268871 .
  • the application CN-A 105713211 describes the linkage of hyaluronate with high contents of the amino acid lysine containing two amino groups. In the absence of amino acids, it is not clear whether or not cross-linking is achieved and, if so, at which extend and which chemical bonds.
  • esterification can be achieved by means of 2-chloro-methylpyridinium iodide.
  • JP-A 2019019201 teaches the use of carbodiimide activating agents such as N,N’-dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), and 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimid (EDC).
  • DCC N,N’-dicyclohexylcarbodiimide
  • DIC diisopropylcarbodiimide
  • EDC 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimid
  • esterification does either nor occur or is extremely slowly and ineffective, even at harsh pH ranges as shown in JP-A 2003/252905.
  • a cross-linked material having beneficial properties can be obtained from a method comprising the reaction of at least some carboxylic acid residues of polysaccharide moieties with at least some hydroxy residues of polysaccharide moieties to form ester bonds cross-linking polysaccharide moieties covalently with each other, wherein the reaction is triggered by one or more triazine-based activating agents.
  • a first aspect relates to a method for preparing a cross-linked material, said method comprising:
  • step (iii) optionally purifying the cross-linked material obtained from step (ii), wherein there are more ester bonds cross-linking polysaccharide moieties covalently with each other than amide bonds cross-linking polysaccharide moieties covalently with each other, wherein step (ii) is conducted in the absence of any activating agent other than triazine-based activating agents, in particular wherein step (ii) is conducted in the absence of carbodiimide activating agents, succinimidyl-based activating agents, glycidyl-based activating agents, paranitrophenol esters, and 2-chloro- methylpyridinium iodide.
  • cross-linked material of the present invention may essentially consist of polysaccharide moieties, which can also found in nature.
  • the cross-linked material of the present invention may also be designated as “cross-linked polysaccharide”, “self-cross-linked material” or “self-cross-linked polysaccharide”.
  • the cross-linked material obtainable from the method of the present invention may have a long-lasting stability.
  • the obtained cross-linked material may form a hydrogel.
  • the cross-linked material may also be used to mimic an extracellular matrix and may, thus, induce cell proliferation and/or cellular migration and/or may serve as a scaffold for cells. It may be well used as a filler (e.g., dermal filer) which may be populated by cells.
  • the cross-linked material of the present invention may have good shear-thinning properties. Preferably, it may have thixotropic properties. Thus, it may be less viscous when stressed. It may be injected very well, while still being rather viscous in its target area (when e.g., administered in a subcutaneous area). Comparably low extrusion forces are required. Gels of high viscosity and low extrusion force are obtainable. It may optionally serve as a super-volumizer.
  • the process of the present invention can be conducted without undue burden and with comparably low efforts.
  • the claimed method is particularly beneficial compared to procedures described in the prior art because it required only two educts (raw materials) in addition to a solvent, i.e., polysaccharide moieties and one or more triazine-based activating agents. Further components such as linkers are not required.
  • xenobiotic linker structures such as, e.g., BDDE
  • BDDE xenobiotic linker structures
  • the omittance of xenobiotic linker structures may enable higher amounts of material administered to a subject, e.g., injected subdermally Furthermore, it may have longevity in a subject’s body after administration.
  • ester bonds may be understood in the broadest sense as generally understood in the art. Typically, an ester bond has the structure -O-CO- or -CO-O-, including tautomeric structures thereof.
  • the polysaccharide moieties are preferably predominantly linked with each other via ester bonds.
  • more than 50% by mole, more than 75% by mole, or even more than 80% by mole, based on all bonds between polysaccharide moieties (interconnecting groups between polysaccharide moieties) may preferably be ester bonds.
  • the cross-linked material comprises a molar ratio of ester groups : amide groups of at least 25 : 1 , preferably at least 50 : 1 , in particular at least 100 : 1.
  • the crosslinked material bears (essentially) no amine groups.
  • carboxylic acid residue and “carboxy residue” may be understood interchangeably as generally understood in the art, i.e.. as residue -COOH or the salt -COO’ thereof.
  • polysaccharide moieties used as educts of the method of the present invention there are preferably more hydroxy residues (-OH) than primary amine groups (-NH2, including salts thereof, i.e., -NH3 + (and counterions)).
  • the polysaccharide moieties comprise a molar ratio of hydroxy residues : primary amine groups of at least 25 : 1 , preferably at least 50 : 1 , in particular at least 100 : 1 . In a preferred embodiment, the polysaccharide moieties bears (essentially) no amine groups.
  • polysaccharide moiety may be understood the broadest sense as any moiety of a polysaccharide known in the art which comprises carboxylic acid residues or salts thereof and hydroxy residues.
  • polysaccharide may be understood the broadest sense as any polysaccharide in the art.
  • at least one polysaccharide moiety comprises at least one carboxylic acid residue or salt thereof.
  • the polysaccharide moieties further comprises hydroxy residues.
  • a polysaccharide may a naturally occurring polysaccharide that may be modified or may be a synthetic polysaccharide.
  • a polysaccharide may be branched or unbranched. It will be understood that the term “polysaccharide moiety” may also include salts and modified forms thereof. In a preferred embodiment, the polysaccharide has not been oxidized.
  • polysaccharide moieties are polymeric moieties of a weight average molecular weight (Mw) of at least 1 kDa (1000 Da), more preferably at least 5 kDa, even more preferably at least 10 kDa.
  • Mw weight average molecular weight
  • the polysaccharide moieties have a weight average molecular weight of at least 50 kDa, preferably at least 200 kDa, in particular in the range of 500 to 4000 kDa.
  • the polysaccharide moieties have a weight average molecular weight (Mw) in the range of from 10 to 10000 kDa, more preferably in the range of from 25 to 7500 kDa, in particular in the range of 50 to 4000 kDa.
  • Mw weight average molecular weight
  • the polysaccharide moieties may have any intrinsic viscosity (e.g. determined by a rheometer such as, e.g., described in the experimental section below). In a preferred embodiment, the polysaccharide moieties may have an intrinsic viscosity of 1 to 4 m 3 /kg (20°C, 1013 hPa, water). In a preferred embodiment, the polysaccharide moieties may have an intrinsic viscosity of 1 .0 to 3.3 m 3 /kg (20°C, 1013 hPa, water).
  • the polysaccharide moieties may have an intrinsic viscosity of 1 .1 to 3.2 m 3 /kg, of 2.0 to 3.1 m 3 /kg, or of 2.5 to 3.0 m 3 /kg (each at 20°C, 1013 hPa, water).
  • the polysaccharide moieties have a weight average molecular weight of 1500 to 3500 kDa (1.5 and 3.5 MDa). More preferably, it may have a weight average molecular weight in the range of from 100 and 5000 kDa, of from 200 to 2000 kDa, of from 250 to 1500 kDa, of from 300 to 1000 kDa, of from 400 to 900 kDa or of from 500 to 900 kDa.
  • the polysaccharide moieties comprise one or more types of sugar acid moieties or salts thereof.
  • polysaccharide moieties comprise one or more types of sugar acid moieties or salts thereof, wherein the one or more types of sugar acid moieties are selected from the group consisting of:
  • (B2) one or more aldonic acid moieties, in particular selected from the group consisting of glyceric acid moiety, xylonic acid moiety, gluconic acid moiety, ascorbic acid moiety, and combinations of two or more thereof;
  • (B3) one or more ulosonic acid moieties, in particular selected from the group consisting of neuraminic acid moiety, ketodeoxyoctulosonic acid moiety, and combinations thereof; and/or
  • aldaric acid moieties in particular selected from the group consisting of tartaric acid moiety, meso-galactaric acid moiety, glucaric acid moiety, and combinations of two or more thereof.
  • the polysaccharide moieties comprise uronic acid moieties. In a preferred embodiment, the polysaccharide moieties comprise glucuronic acid moieties. In a preferred embodiment, the polysaccharide moieties comprise D-glucuronic acid moieties.
  • the polysaccharide moieties comprise or consist of D- sugar moieties. In an alternative embodiment, the polysaccharide moieties comprise or consist of L-sugar moieties. In an alternative embodiment, the polysaccharide moieties comprise or consist of a combination of D- sugar moieties and L-sugar moieties. For instance, in such combination, racemic mixture of sugar moieties may be comprised or specific sugar moieties are D-sugar moieties and others are L- sugar moieties. In a preferred embodiment, the polysaccharide moieties comprise or consist of one or more glycosaminoglycan moieties.
  • the polysaccharide moieties are selected from the group consisting of hyaluronic acid (HA) moieties, heparosan moieties, heparin, chondroitin sulphate, and mixtures of two or more thereof.
  • the polysaccharide moieties comprise or consist of hyaluronic acid, glycerol-grafted hyaluronic acid, heparosan, chondroitin sulfate, and carboxymethyl cellulose.
  • Such polysaccharides comprising carboxylic acid groups are also commercially available.
  • the polysaccharide moieties comprise or consist of one or more hyaluronic acid moieties. It will be understood that this may also comprises salts thereof.
  • the cross-linked material of the present invention is a gel.
  • the cross-linked material of the present invention is a polysaccharide-based gel.
  • the cross-linked material of the present invention is a hyaluronic acid-based gel (HA gel).
  • HA gel hyaluronic acid-based gel
  • Such material may optionally also be designated as self-cross-linked hyaluronic acid (HA)
  • Hyaluronic acid (also: HA, hyaluronate, or hyaluronan) may be understood in the broadest sense as any hyaluronic acid in the art. It may be polysaccharide moiety that contains hyaluronic acid moieties (also hyaluronic acid units), preferably comprises at least 50 mol% of hyaluronic acid moieties, more preferably at least 75 mol%, even more preferably at least 80 mol%, even more preferably at least 90 mol%, referred to the whole content of saccharide moieties in the polysaccharide, of hyaluronic acid moieties.
  • Hyaluronic acid may optionally comprise one or more saccharide moieties other than hyaluronic acid.
  • hyaluronic acid is a naturally glycosaminoglycan composed of linked repeating units of N-acetyl-D-glucosamine and D-glucuronic acid ([alpha-1 ,4-D-glucuronic acid-beta-1 ,3-N-acetyl-D-glucosamine] n ).
  • the repeating/monomeric unit of hyaluronic acid may be exemplarity the following or a salt thereof:
  • a repeating structure motif of hyaluronic acid may be exemplarity the following or a salt thereof:
  • Hyaluronic acid may be used as described in WO 2022/268871 .
  • the weight average molecular weight (Mw) of hyaluronic acid in the context of the present invention is preferably at least 1 kDa (1000 Da), more preferably at least 5 kDa, even more preferably at least 10 kDa, even more preferably at least 50 kDa, even more preferably at least 100 kDa, even more preferably at least 200 kDa, even more preferably at least 300 kDa or more.
  • the polysaccharide moieties have a weight average molecular weight as laid out above.
  • Heparosan may be understood in the broadest sense as any heparosan. In a preferred embodiment, it may be such as described in WO 2015/149941 .
  • Heparosan is a biopolymer belonging to the glycosaminoglycan (GAG) family of polysaccharides.
  • heparosan is highly similar to that of hyaluronic acid (HA) since it has the same monosaccharide component sugars as hyaluronic acid and differs from HA only in that the beta-(1 ,3) glycosidic bond between the glucuronic acid (GlclIA) and the /V-acetylglucosamine (GIcNAc) in HA is replaced by a beta- (1 ,4) glycosidic bond in HEP and in that the beta-(1 ,4) glycosidic bond between /V- acetylglucosamine (GIcNAc) and the glucuronic acid (GlclIA) in HA is replaced by an alpha-(1 ,4) glycosidic bond in HEP:
  • heparosan has excellent biocompatibility. Heparosan carries a high number of negative charges and hydroxy residues and is therefore highly hydrophilic, which increases tissue compatibility. Furthermore, due to the fact that heparosan polymers, even after modification, still comprise stretches that occur in natural heparan sulfate and heparin polymers, heparosan is typically non- immunogenic (e.g., does not induce antibodies). Moreover, due to the structural similarity between heparosan and hyaluronic acid, the same chemical modifications, including oxidation to aldehydes as that known for hyaluronic acid may be made on the functional groups.
  • the molecular weight (Mw) of the heparosan polymers used in the context of the present invention may have any molecular weight.
  • Chondroitin sulfate may be understood in the broadest sense as generally understood in the art. In a n aqueous environment, it may be a structure comprising the following repeating/monomeric units (counterions are not depicted and may be any cations such as, e.g, sodium):
  • the polysaccharide moieties may be one or more types of polysaccharide moieties. These may be different in molecular size and/or may be different in the composition of monomeric units and/or may be different in chemical structure. Optionally, different polysaccharide moieties may be different types of polysaccharide moieties.
  • the polysaccharide moieties, in particular hyaluronic acid moieties have at least two different molecular weights each comprising primary amino residues or salts thereof. In other words, the polysaccharide moieties may also be a mixture of polysaccharide moieties of different molecular weight.
  • the polysaccharide moieties have at least two different molecular weights and at least one polysaccharide moiety has, preferably at least two polysaccharide moieties, in particular all polysaccharide moieties, each have a molecular weight in the range of 10 to 10000 kDa, in the range of 100 to 10000 kDa, or in the range of 100 to 5000 kDa.
  • the total amount of polysaccharide moieties does not comprise more than 20% by weight, does not comprise more than 10% by weight, does not comprise more than 5% by weight, does not comprise more than 1 % by weight, does not comprise more than 0.5% by weight, or does not comprise more than 0.1 % by weight, based on the total amount of polysaccharide moieties, of polysaccharide moieties of molecular weights of less than 200 kDa.
  • the polysaccharide moieties comprise or consist of at least two hyaluronic acid moieties having at least two different molecular weights and at least one hyaluronic acid moiety has, preferably at least two hyaluronic acid moieties both have, in particular all hyaluronic acid moieties each have, a molecular weight in the range of 10 to 10000 kDa, in the range of 100 to 10000 kDa, or in the range of 100 to 5000 kDa.
  • the polysaccharide moieties comprise or consist of at least two hyaluronic acid moieties having at least two different molecular weights and at least one hyaluronic acid moiety has, preferably at least two hyaluronic acid moieties both have, in particular all hyaluronic acid moieties each have, a molecular weight in the range of 1500 to 3500 kDa.
  • the triazine-based activating agent may be used in any content suitable for crosslinking carboxylic acid residues of the polysaccharide moieties with at least some of the hydroxy residues of the polysaccharide moieties to form ester bonds thereby cross-linking polysaccharide moieties covalently with each other.
  • a triazine-based activating agent activates the carboxylic acid residues of the polysaccharide moieties.
  • the content of triazine-based activating agent may be reasonably defined as molar equivalents (eq.) related to the carboxylic acid residues of the polysaccharide moieties.
  • carboxylic acid residues also embrace salts thereof.
  • molar equivalents (eq.) of the triazine-based activating agent is defined as molar ratio of [triazine-based activating agent] : [carboxylic acid residues of the polysaccharide moieties].
  • each HA monomeric/repeating unit when used as sodium salt bears one carboxylic acid residue.
  • the crosslinking degree can be adjusted with different molar equivalents (eq.) of triazine-based activating agent.
  • the molar ratio of [triazine-based activating agent] : [carboxylic acid residues of the polysaccharide moieties] is in the range of 1 : 100 to 100 : 1 , preferably in the range of 1 :10 to 10 : 1 , more preferably in the range of 1 :5 to 5 : 1 or in the range of 1 :2 to 2 : 1 .
  • a triazine-based activating agent may be any compound based on a triazine core structure that effects reaction of carboxylic acid residues with hydroxy residues thereby forming ester bonds. It will be understood that it is mainly meant that an activating agent is a compound that effects reaction of carboxylic acid residues of the polysaccharide moieties with hydroxy residues of the polysaccharide moieties thereby forming ester bonds.
  • an activating agent is typically not covalently included in the cross-linked material. Thus, it may be typically optionally removed from the cross-linked material of the present invention by any means such as, e.g., washing, filtration, etc.
  • a triazine-based activating agent may have any structure that comprises a triazine core that is suitable for cross-linking carboxylic acid residues of the polysaccharide moieties with at least some of the hydroxy residues of the polysaccharide moieties to form ester bonds thereby cross-linking polysaccharide moieties covalently with each other.
  • a triazine-based activating agent may have the structure: wherein R 1 , R 2 and R 3 are independently from each other any residue, such as, e.g., each independently a residue selected from the group consisting of hydrogen, deuterium, Ce-Cw-aryl, C2-Cio-heteroaryl, linear or branched Ci-Cio-(cyclo)alkyl, linear or branched Ci-Cio-(cyclo)alkoxy, linear or branched C1-C10- hetero(cyclo)alkyl, linear or branched C2-Cio-(cyclo)alkenyl, C2-C10- hetero(cyclo)alkenyl, linear or branched C2-Cio-(cyclo)alkinyl, and C2-C10- hetero(cyclo)alkenyl, wherein each of the aforementioned residues is optionally substituted with one or more residues selected from the group consisting of halogen, Ce-Cw-aryl, C
  • At least one or the residues R 1 , R 2 and R 3 is an optionally substituted morpholinium residue. In a preferred embodiment, at least one or the residues R 1 , R 2 and R 3 is a Ci-C4-alkyl-morpholinium residue. In a preferred embodiment, at least one or the residues R 1 , R 2 and R 3 is a methylmorpholinium residue. In a preferred embodiment, at least one or the residues R 1 , R 2 and R 3 is an optionally substituted linear or branched Ci-Cio-(cyclo)alkoxy residue.
  • At least one or the residues R 1 , R 2 and R 3 is an optionally substituted linear or branched Ci-C4-alkoxy residue. In a preferred embodiment, at least one or the residues R 1 , R 2 and R 3 is an optionally substituted linear or branched methoxy residue.
  • the triazine-based activating agent has a molecular weight of not more than 1500 g/mol, of not more than 1000 g/mol, of not more than 500 g/mol, of not more than 400 g/mol,
  • the one or more activating agents are selected from the group consisting of 4-(4,6-dimethoxy-1 ,3,5-triazin-2-yl)-4-methylmorpholinium (DMTMM) or a salt thereof, and/or 2-chloro-4,6,-dimethoxy-1 ,3,5-triazine or a salt thereof, and combinations thereof.
  • DTMM 4-(4,6-dimethoxy-1 ,3,5-triazin-2-yl)-4-methylmorpholinium
  • 2-chloro-4,6,-dimethoxy-1 ,3,5-triazine or a salt thereof and combinations thereof.
  • the activating agent is 4-(4,6-dimethoxy-1 ,3,5-triazin-2- yl)-4-methylmorpholinium (DMTMM) or a salt thereof,
  • a salt of DMTMM is preferably a salt wherein the counter-ion is an anion that is cosmetically and/or pharmaceutically acceptable such as, e .g., chloride, acetate, bicarbonate (hydrogen carbonate), or a mixture of two or more anions.
  • the activating agent is 4-(4,6-dimethoxy-1 ,3,5-triazin-2- yl)-4-methylmorpholinium chloride (CAS No. 3945-69-5).
  • DMTMM is considered as having a comparably low and essentially negligible toxicity, is not cancerogenic, not mutagenic, and not teratogenic/reprotoxic in the generally used amounts. Thus, it is particularly well usable for preparing a soft-tissue filler such as a dermal or connective tissue filler.
  • DMTMM When using DMTMM or a salt thereof as activating agent, 4-methylmorpholine (NMM) and/or 4,6-dimethoxy-1 ,3-5-triazine-2-ol (DMT) may be formed as degradation product(s).
  • NMM 4-methylmorpholine
  • DMT 4,6-dimethoxy-1 ,3-5-triazine-2-ol
  • the chloride salt of DMTMM may be used as as activating agent:
  • the method is further characterized in that it does not comprise at least one of the following:
  • a carbodiimide-based activating agent in particular selected from the group consisting of N,N’-dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimid (EDC), and combinations of two or more thereof;
  • DCC N,N’-dicyclohexylcarbodiimide
  • DIC diisopropylcarbodiimide
  • EDC 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimid
  • polysaccharide moieties having primary amine groups, thiol groups, imide groups, imine groups, or epoxy groups.
  • the method is further characterized in that it does not comprise at least two, more preferably at least three, in particular all of the following:
  • a carbodiimide-based activating agent in particular selected from the group consisting of N,N’-dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimid (EDC), and combinations of two or more thereof;
  • DCC N,N’-dicyclohexylcarbodiimide
  • DIC diisopropylcarbodiimide
  • EDC 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimid
  • the solvent may be any solvent that is suitable for reacting carboxylic acid residues or salts thereof and hydroxy residues of the polysaccharide moieties.
  • the solvent is suitable for dissolving or suspending the polysaccharide moieties and dissolving the triazine-based activating agents.
  • the solvent is suitable for dissolving the polysaccharide and the triazine-based activating agents.
  • the solvent is a polar solvent.
  • the solvent is a protic solvent.
  • the solvent is a protic polar solvent.
  • the solvent comprises more than 50 wt.%, of at least 60 wt.%, of at least 70 wt.%, of at least 80 wt.%, of at least 90 wt.%, of at least 95 wt.%, or even 100 wt.%, referred to the total mass of the solvent, of one or more components selected from the group consisting of: water; one or more alcohols, preferably one or more Ci-Cs-alcohols, more preferably, one or more Ci-Cs-alcohols selected from the group consisting of methanol, ethanol, n- propanol, isopropanol, n-butanol (1 -butanol), sec-butanol (2-butanol) isobutanol, (2- methylpropan-1 -ol), tert-butanol (2-methylpropanol), pentan-1 -ol, 2-methylbutan-1- ol, 3-methylbutan-1
  • the solvent is an aqueous solution.
  • An aqueous solvent may be understood in the broadest sense as a solvent that comprises a water content by weight of more than 50 wt.%, of at least 60 wt.%, of at least 70 wt.%, of at least 80 wt.%, of at least 90 wt.%, of at least 95 wt.%, or even 100 wt.%, referred to the total mass of the solvent.
  • an aqueous buffer comprises, in addition to water, one or more components selected from the group consisting of one or more alcohols (in particular one or more C1-C5- alcohols such as, e.g., methanol, ethanol, n-propanol, isopropanol, n-butanol (1- butanol), sec-butanol (2-butanol) isobutanol, (2-methyl-propan-1 -ol), tert-butanol (2-methylpropanol), pentan-1 -ol, 2-methylbutan-1-ol, 3-methylbutan-1 -ol, 2,2- dimethylpropan-1 -ol, pentan-2 -ol, 3-methylbutan-2-ol, pentan-3-ol, and/or 2- methylbutan-2-ol), one or more primary amines (in particular one or more C1-C5- amines), one or more carbonic acids (in particular
  • the solvent is an aqueous buffer (e.g., phosphate buffered saline (PBS), Tris buffer, borate buffer, acetic acid-buffered buffer, etc.).
  • a hydroalcoholic solvent is used such as, e.g., a mixture of water with ethanol, methanol, propanol, butanol, and/or pentanol.
  • water is used as solvent.
  • the solvent is an aqueous buffer having a pH in the range of 5 to 9, in particular 6 to 8.
  • the solvent may be an aqueous buffer having a pH in the range of 6.1 to 7.9, of 6.5 to 7.7, of 6.7 to 7.5, or of 7.0 to 7.5,
  • Water as used herein may be understood in the broadest sense.
  • water is deionized water, distilled water, or tap water, in particular deionized water or distilled water.
  • the method does not comprise a purification step (iii). In another embodiment, the method comprises at least one purification step (iii). In one embodiment, the method comprises at least one step (iii) of purifying the crosslinked material by filtration, washing and/or dialysis, in particular crossflow filtration, diaf iltration and/or dead-end filtration;
  • Dialysis may be conducted by any means.
  • dialysis is using dialysis membranes having a molecular weight cut-off (MWCO) of 1 to 25 kDa, of 5 to 20 kDa, or of 10 to 15 kDa.
  • Purification time may be adapted to the molecule structures and may be in the range of at least 1 hour, at least 6 hours, 12 to 78 hours, 1 to 7 days, or 1 to 3 days.
  • the swelling ratio may be optionally controlled by the weight of the membranes and the dialysis may be stopped once the product shows the desired cross-linked material concentration.
  • filtration may be crossflow filtration, dead-end filtration, or a combination of both. Filtration may be performed by any means.
  • the a filter may have any pore size suitable for purifying the cross-linked material, i.e., preferably withholding the cross-linked material and allowing the passage of reactants and optionally of non-reacted polysaccharides.
  • the pore size may be in a range of 5 nm to 2 pm, more particularly a pore size of 30 nm to 600 nm, more particularly a pore size of 80 nm to 300 nm, particularly a pore size of 5 nm to 60 nm.
  • a filter may be of any material such as, e.g., ceramic, metal, polymer material, or a combination thereof.
  • filtration may be dynamic filtration such as, e.g., described in WO 2020/030629.
  • step (iii) may optionally comprise dynamic filtration of the cross-linked material, optionally, comprising the following steps: a) transferring the cross-linked material in a dynamic filtration device which is equipped with semipermeable filter disc(s) and diaf iltrating the gel comprising the steps of: i) concentrating the cross-linked material by applying a rotational speed within the range of 20 1/min to 500 1/min and a overpressure within the range of 0.5 to 6 bar to a predetermined concentration; or pumping the cross-linked material directly into the process chamber of the dynamic filtration device; ii) conducting a diafiltration to reduce unwanted molecules by applying a rotational speed within the range of 20 1/min to 500 1/min and a overpressure within the range of 0.5 to 6 bar; b) optionally adding a mixture comprising a non-cross-linked material and water to the cross-linked material.
  • the dynamic filtration device is equipped with 1 to 10 semipermeable filter disc(s).
  • any rotational speed and pressure may be used, such as, e.g., a rotational speed within the range of 20 1/min to 500 1/min and a pressure within the range of 0.5 to 3 bar.
  • any concentration may be used such as e.g., 10 to 70 mg/g.
  • crossflow filtration is dynamic crossflow filtration (DCF).
  • DCF dynamic crossflow filtration
  • the method may be further characterized in that it comprises a step (iii) of purifying the crosslinked material by DCF.
  • DCF may be such as described in WO 2020/030629.
  • one or more further components e.g., one or more local anesthetics (e.g., as laid out below such as, e.g., lidocaine), one or more cell proliferation factors, one or more dyes, and combinations of two or more thereof
  • one or more further components e.g., one or more local anesthetics (e.g., as laid out below such as, e.g., lidocaine), one or more cell proliferation factors, one or more dyes, and combinations of two or more thereof
  • one or more further components e.g., one or more local anesthetics (e.g., as laid out below such as, e.g., lidocaine), one or more cell proliferation factors, one or more dyes, and combinations of two or more thereof
  • one or more further components e.g., one or more local anesthetics (e.g., as laid out below such as, e.g., lidocaine), one or more cell proliferation factors, one or more dyes
  • steps (i) and (ii) are conducted in a single batch. In another embodiment, steps (i) and (ii) are conducted in separate batches. Steps (i) and (ii) and optional step (iii) any be each conducted at any temperature range. In a preferred embodiment, step (i) is conducted at a temperature in the range of from 5 to 90°C, preferably 18 to 60°C, in particular more preferably 18 to 25°C or 20°C to 50°C. In a preferred embodiment, step (ii) is conducted at a temperature in the range of from 5 to 90°C, preferably 18 to 60°C, in particular 20°C to 50°C.
  • step (iii) is conducted at a temperature in the range of from 5 to 90°C, or 18 to 60°C, or 20°C to 50°C.
  • steps (i) and (ii) and optional step (iii) are conducted at a temperature in the range of from 5 to 90°C, preferably 18 to 60°C, in particular 20°C to 50°C.
  • steps (i) and (ii) are conducted at temperatures that do not different in more than 10°C, do not different in more than 5°C, or do not different in more than 2°C.
  • steps (i) and/or (ii) and/or step (iii) may be conducted at a temperature of (approximately) 18°C, of (approximately) 19°C, of (approximately) 20°C, of (approximately) 21 °C, of (approximately) 22°C, of
  • Steps (i) and (ii) and optional step (iii) may be conducted at any pressure.
  • pressure may be ambient pressure (e.g., often approximately 970 to 1100 hPa outer pressure).
  • Step (i) of contacting the components with each other may be conducted by any means.
  • the method is further characterized in that step (i) involves the mixing of the components, i.e., the polysaccharide and the one or more activating agents, and one or more solvents, and optional one or more further components.
  • Such mixing may be conducted by any means such as, e.g., by means of stirring and/or shaking.
  • the polysaccharide moieties are mixed with the solvents or parts of the solvent before contacting it with the one or more activating agents.
  • This step may contain an incubation of the mixture of the polysaccharide moieties and the solvents or parts of the solvent (also: pre-swelling). For instance, such optional incubation step may be conducted (e.g., at a temperature of 4 to 40°C) for at least 10 min, for 30 min to 7 days, for 1 hour to 2 days, for 6 to 36 hours, or for 12 to 24 hours.
  • the one or more activating agents may be optionally premixed with parts of the solvent and subsequently added to the mixture of the polysaccharide moieties and the solvents or parts of the solvent.
  • reaction step (ii) may be conducted as long as suitable for achieving the desired reaction of the carboxylic acid residues or salts thereof with the hydroxyl residues.
  • Step (ii) may be conducted for any time suitable for this purpose.
  • step (ii) may be conducted for 1 min to 1 week or longer, 2 min to 5 days, 3 min to 4 days, 5 min to 72 hours, 5 min to 24 hours, 10 min to 12 hours, 30 min to 6 hours, 1 hour to 5 hours, or 2 to 4 hours.
  • Step (ii) may be conducted for at any temperature suitable for this purpose such as, e.g., at 0°C to 100°C, at 4°C to 95°C, at 10°C to 70°C, at 15°C to 30°C, at 18 to 25°C, at 20°C to 70°C, at 20°C to 40°C, or at 60°C to 70°C.
  • the step (ii) is conducted for not more than 72 h, for not more than 48 h, or for not more than 24 h.
  • the step (ii) is conducted for at least 10 min, preferably for 15 min to 48 h, in particular for 30 min to 18 h.
  • the method is further characterized in that the step (ii) is conducted at a temperature in the range of from 5 to 90°C, preferably 18 to 60°C, in particular 20°C to 50°C, for at least 10 min, preferably for 15 min to 48 h, in particular for 30 min to 18 h.
  • the method is further characterized in that the step (ii) is conducted at a temperature in the range of from 5 to 90°C for at least 10 min.
  • the method is further characterized in that the step (ii) is conducted at a temperature in the range of 18 to 60°C for 30 min to 18 h.
  • Step (ii) may be conducted at any pH. For example, it may be conducted at a pH in the range of 5 to 9, in particular 6 to 8, of 6.1 to 7.9, of 6.5 to 7.7, of 6.7 to 7.5, or of 7.0 to 7.5,
  • the polysaccharide moieties may be used at any concentration range. In a preferred embodiment, 0.01 to 800 mg/mL, or 0.1 to 500 mg/mL, or .5 to 200 mg/mL of polysaccharide moieties is used. In a preferred embodiment, 1 to 100 mg/mL, or 2 to 75 mg/mL, or 5 to 50 mg/mL, or 20-25 mg/mL, or 25 to 35 mg/mL, of polysaccharide moieties is used.
  • step (iii) may be conducted for any time suitable for this purpose.
  • step (iii) may be conducted for 1 min to 1 week or longer, 2 min to 5 days, 3 min to 4 days, 5 min to 72 hours, 5 min to 24 hours, 10 min to 12 hours, 30 min to 6 hours, 1 hour to 5 hours, or 2 to 4 hours.
  • Step (iii) may be conducted for at any temperature suitable for this purpose such as, e.g., at 0°C to 100°C, at 4°C to 95°C, at 10°C to 70°C, at 15°C to 30°C, at 18 to 25°C, at 20°C to 70°C, at 20°C to 40°C, or at 60°C to 70°C.
  • the method is further characterized in that:
  • step (a) it comprises a step (iii) of purifying the cross-linked material by filtration, washing and/or dialysis, in particular crossflow filtration, diafiltration and/or dead-end filtration;
  • steps (i) and (ii) are conducted in a single batch
  • steps (i) and (ii) and optional step (iii) are conducted at a temperature in the range of from 5 to 90°C, preferably 18 to 60°C, in particular 20°C to 50°C; and/or
  • step (d) the step (ii) is conducted for at least 10 min, preferably for 15 min to 48 h, in particular for 30 min to 18 h.
  • the method comprises:
  • step (iii) optionally purifying the cross-linked material obtained from step (ii).
  • the obtained cross-linked material may be optionally treated further. For instance, it may be optionally homogenized and/or passed through a sieve (screening).
  • a sieve screening
  • filter and mesh may be understood interchangeably. This may result in a particularly homogeneous material (e.g., hydrogel).
  • the cross-linked material may be subjected to sterilization.
  • the method comprises the following steps:
  • step (iii) optionally purifying the cross-linked material obtained from step (ii) by dialysis;
  • the method comprises:
  • polysaccharide moieties comprising carboxylic acid residues or salts thereof and hydroxy residues having a weight average molecular weight of at least 50 kDa, wherein the polysaccharide moieties are pre-mixed with parts of the aqueous solvent and incubated (e.g., for 30 min to 7 days),
  • step (iii) optionally purifying the cross-linked material obtained from step (ii) by dialysis;
  • cross-linked material obtainable from a method of the present invention bears special technical characteristics such as structural characteristics and the absence of harsh (bi)functional linkers and activating agents.
  • a further aspect of the present invention relates to a cross-linked material obtainable from a method of the present invention.
  • the cross-linked material has been prepared by using DMTMM as activating agent.
  • the cross-linked material in particular before final purification, comprises:
  • the cross-linked material in particular before final purification, comprises NMM and/or DMT.
  • the cross-linked material, in particular before final purification comprises up to 0.1 % by weight, preferably 0.01 to 1000 ppm, 0.1 to 100 ppm, or 1 to 50 ppm of NMM and/or DMT, referred to the total weight of the cross-linked material (gel).
  • a further aspect of the present invention relates to a cross-linked material comprising or consisting of one or more hyaluronic acid moieties having a weight average molecular weight of at least 50 kDa, wherein the hyaluronic acid moieties are covalently cross-linker with each other via ester bonds without an interconnecting linker structure, further characterized in that the cross-linked material does not comprise diimide groups, epoxy groups or xenobiotic linker moieties.
  • the term “without an interconnecting linker structure” may be understood in the broadest sense in that no further chemical moiety that does not originate from (also: is not present in) polysaccharide moieties (e.g., hyaluronic acid moieties) is introduced into the chemical structure that conjugates polysaccharide moieties with ester bonds.
  • the ester bonds are preferably formed from inclusion of an oxygen atom originating from polysaccharide moieties (e.g., hyaluronic acid moieties) and from inclusion of a carbon atom originating from polysaccharide moieties (e.g., hyaluronic acid moieties).
  • the cross-linked material is further characterized in that it does not comprise imide groups or diimide groups. In a preferred embodiment, the cross-linked material is further characterized in that it does not comprise imine groups. In a preferred embodiment, the cross-linked material is further characterized in that it does not comprise epoxy groups. In a preferred embodiment, the crosslinked material is further characterized in that it does not comprise xenobiotic linker moieties groups.
  • the cross-linked material is further characterized in that it does not comprise:
  • the cross-linked material is further characterized in that it does not comprise:
  • the cross-linked material is obtained from a method of the present invention.
  • the cross-linked material may be immediately used or may be stored.
  • it may be stored at any condition suitable for this purpose such as, e.g., at ambient temperature (e.g., 18 to 30°C, preferably 18 to 25°C), in a fridge (e.g., at 0 to 15°C, preferably 3 to 10°C), in a freezer (e.g., -30 to 0°C, preferably -25 to -10°C), in a deep freezer (e.g., -100 to -200°C, preferably -90 to -55°C), on liquid nitrogen, on dry ice, or even one or more liquid noble gases.
  • It may be stored at dry state, as a hydrogel, as a gel containing other non-aqueous solvents, and/or as a suspension, emulsion, colloid or solution.
  • the solvent used in steps (i) and (ii) and/or optionally in step (iii) may optionally be partly or completely removed.
  • the solvent used in steps (i) and (ii) and/or optionally in step (iii) may alternatively optionally also be maintained in the cross-linked material.
  • the solvent used in steps (i) and (ii) and/or optionally in step (iii) may be removed by any means such as, e.g., by replacing it by another solvent (e.g., another aqueous buffer) and/or by evaporation.
  • the cross-linked material may be used for any purpose and in any form.
  • it may be gel when comprising a liquid or viscous medium in its voids.
  • such liquid or viscous medium may be any liquid or viscous medium that does not disintegrate the cross-linked material.
  • the liquid or viscous medium is an aqueous liquid.
  • the cross-linked material of the present invention can be used for preparing a hydrogel.
  • a hydrogel comprising:
  • (C) optionally one or more further pharmaceutically or cosmetically acceptable agents, in particular one or more local anesthetics.
  • the present invention also relates to a method for preparing a hydrogel.
  • such method may comprise a step of adding an aqueous buffer to a purified cross-linked material.
  • the cross-linked material and/or the hydrogel of the present invention may be used for any purpose. For instance these may be used as an injectable composition.
  • a further aspect of the present invention relates to an injectable composition
  • an injectable composition comprising a cross-linked material or a hydrogel of the present invention, wherein the cross-linked material preferably is a super-volumizer.
  • the cross-linked material, hydrogel and/or the injectable composition of the present invention is usable as a soft-tissue filler, in particular a dermal filler or a connective tissue filler.
  • a liquid or viscous carrier according the present invention as comprised in the injectable composition may be any injectable carrier.
  • the liquid or viscous carrier is a pharmaceutically and/or cosmetically acceptable carrier, therefore, a carrier that is non-toxic to the mammal, in particular a human, when administered to the mammal in the sense of the present invention.
  • the liquid or viscous carrier may preferably comprise or consist of one or more solvents such as, e.g., water, an aqueous buffer (e.g., a saline or phosphate buffered saline), dimethyl sulfoxide (DMSO), ethanol, vegetable oil, paraffin oil or combinations thereof.
  • the liquid or viscous carrier comprises or consists of an apyrogenic isotonic buffer, more particularly a physiological saline solution or a buffered physiological saline solution.
  • An optionally present further components may be any components.
  • such further component may be selected from the group consisting of one or more local anesthetics, one or more cell proliferation factors, one or more dyes, and combinations of two or more thereof.
  • Such further components may be added at any time such as before, during or after purifying the cross-linked material.
  • one or more further components may be added during conducting a purifying step (iii).
  • one or more further components may be added to the prepared and optionally purified cross-linked material.
  • a local anesthetic may make injection into an individual more comfortable.
  • a cell proliferation factor may improve cellular invasion into an administered cross-linked material of the present invention.
  • a dye may either improve localization of the injection (e.g., a pharmaceutically acceptable fluorescent dye like fluorescein or rhodamine) or may improve invisibility of the otherwise whitish cross-linked material (e.g., by rendering it flesh-colored). Any other pharmaceutically active compound may also be added. Then, the cross-linked material of the present invention may also serve as a retard form for administration.
  • Suitable local anesthetics for use herein include, but are not limited to, ambucaine, amolanone, amylocaine, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butamben, butanilicaine, butethamine, butoxycaine, carticaine, chloroprocaine, cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethysoquin, dimethocaine, diperodon, dycyclonine, ecgonidine, ecgonine, ethyl chloride, etidocaine, beta-eucaine, euprocin, fenalcomine, formocaine, hexylcaine, hydroxytetracaine, isobutyl p-aminobenzoate, leucinocaine mesylate, levoxadrol, lidocaine, mepivacaine, meprylcaine
  • hydrogel and/or the injectable composition of the present invention can be provided in different packaging. It may be stored at any condition suitable for this purpose such as, e.g., at ambient temperature (e.g., 18 to 30°C, preferably 18 to 25°C), in a fridge (e.g., at 0 to 15°C, preferably 3 to 10°C), in a freezer (e.g., -30 to 0°C, preferably -25 to - 10°C), in a deep freezer (e.g., -100 to -200°C, preferably -90 to -55°C), on liquid nitrogen, on dry ice, or even one or more liquid noble gases.
  • ambient temperature e.g., 18 to 30°C, preferably 18 to 25°C
  • a fridge e.g., at 0 to 15°C, preferably 3 to 10°C
  • a freezer e.g., -30 to 0°C, preferably -25 to - 10°C
  • a deep freezer
  • it may be provided in a vial, in a syringe. It may be administered to a subject via injection (e.g., via a syringe or a drip). It may be stored at dry state, as a hydrogen, as a gel containing other non-aqueous solvents, and/or as a suspension, emulsion, colloid or solution.
  • the present invention also refers to the use of an injectable composition according to the present invention for cosmetic applications. More preferably, the present invention also refers to the use of an injectable composition according to the present invention for cosmetic applications comprising facial and body re-shaping and rejuvenation.
  • cosmetic applications and cosmetic uses may be understood in the broadest sense as any non-therapeutic application intended for improving appearance. It may also be designated as aesthetic application and aesthetic use, respectively. It will be understood that, in the context of the present invention, a cosmetic application and cosmetic use may include any administration route that may optionally include an injection of the respective material and/or topical administration of the respective material or another suitable administration route.
  • a further aspect of the present invention relates to the use of an injectable composition of the present invention for cosmetic applications comprising facial and body re-shaping and rejuvenation, preferably including filling of wrinkles, improving facial lines, breast reconstruction or augmentation, rejuvenation of the skin, buttocks augmentation, remodeling of cheekbones, soft-tissue augmentation, filling facial wrinkles, improving glabellar lines, improving nasolabial folds, improving marionette lines, improving buccal commissures, improving peri-lip wrinkles, improving crow’s feet, improving subdermal support of the brows, malar and buccal fat pads, improving tear troughs, improving nose appearance, augmentation of lips, augmentation of cheeks, augmentation of peroral region, augmentation of infraorbital region, resolving facial asymmetries, improving jawlines, augmentation of chin, or a combination of two or more thereof.
  • This use may be a therapeutic and/or cosmetic use.
  • the present invention relates to the use of an injectable composition of the present invention for reducing facial folds.
  • the use of the present invention may be a cosmetic use, preferably a non-therapeutic use.
  • the use of the present invention may be conducted by cosmetics, cosmetic professionals or health care professionals.
  • an injectable composition of the present invention is for improvement of skin quality, treatment of fine lines, treatment of deep lines or volume restoration, or as super-volumizing filler for breast or buttock augmentation.
  • the present invention also relates to a method of facial and body reshaping and rejuvenation (preferably including the above specific uses), said method comprising administering the injectable composition according to the present invention.
  • the present invention relates to an injectable composition according to the present invention for use in a method for facial and body re-shaping and rejuvenation, preferably including filling of wrinkles, improving facial lines, breast reconstruction or augmentation, rejuvenation of the skin, buttocks augmentation, remodeling of cheekbones, soft-tissue augmentation, filling facial wrinkles, improving glabellar lines, improving nasolabial folds, improving marionette lines, improving buccal commissures, improving peri-lip wrinkles, improving crow’s feet, improving subdermal support of the brows, malar and buccal fat pads, improving tear troughs, improving nose appearance, augmentation of lips, augmentation of cheeks, augmentation of peroral region, augmentation of infraorbital region, resolving facial asymmetries, improving jawlines, augmentation of chin, or a combination of two or more thereof.
  • the present invention also relates to a method for use in a method for facial and body re-shaping and rejuvenation, preferably including filling of wrinkles, improving facial lines, breast reconstruction or augmentation, rejuvenation of the skin, buttocks augmentation, remodeling of cheekbones, soft-tissue augmentation, filling facial wrinkles, improving glabellar lines, improving nasolabial folds, improving marionette lines, improving buccal commissures, improving peri-lip wrinkles, improving crow’s feet, improving subdermal support of the brows, malar and buccal fat pads, improving tear troughs, improving nose appearance, augmentation of lips, augmentation of cheeks, augmentation of peroral region, augmentation of infraorbital region, resolving facial asymmetries, improving jawlines, augmentation of chin, or a combination of two or more thereof, wherein the a sufficient amount of the injectable composition according to the present invention is administered to a subject in need thereof.
  • a subject may be any animal, typically a mammal, preferably a domestic mammal or a human. Particularly preferably, an individual is a human.
  • a treated human can also be designated as a patient, independent on his/her health state.
  • Administration may conducted by any means.
  • administration is administration via a needle.
  • administration is administration via a syringe, in particular intradermal or subdermal administration via a syringe.
  • Administration may be manual administration, administration using a mechanical pump, or even automated administration.
  • a Syringe One system may be used for administration.
  • the cross-linked material of the present invention as well as the injectable composition of the present invention may be used for any purpose.
  • the cross-linked material of the present invention as well as the injectable composition of the present invention may be used for cosmetic and/or therapeutic uses.
  • the injectable composition may be a filler, in particular a soft tissue filler such as, e.g., soft-tissue filler, in particular a dermal filler or a connective tissue filler.
  • the present invention also refers to the use of an injectable composition according to the present invention as a filler such as a soft-tissue filler, in particular a dermal filler or a connective tissue filler. It may be used as a super-volumizer. In this context, it may be used as a hydrogel.
  • a filler such as a soft-tissue filler, in particular a dermal filler or a connective tissue filler. It may be used as a super-volumizer. In this context, it may be used as a hydrogel.
  • filler may be understood in the broadest sense as any agent that can be used to fill a cavity or to serve as a soft tissue filler, preferably a soft tissue filler.
  • a soft tissue filler may be understood in the broadest sense as a material designed to add volume to areas of soft tissue deficiency.
  • a filler may be administered to any location and by any type of injection and may be suitable for uses in cosmetic/aesthetic applications as well as for therapeutic purposes.
  • a filler may generally be any composition that adds, replaces or augments volume under the skin leading to, e.g., smoothened skin wrinkles, augmented lips, improved skin appearance, or treated scars. It is generally used in the dermis area, such as below the epidermis or above the hypodermis and as such may be injected subcutaneously, hypodermically or intradermally, or some combinations.
  • An injectable composition within the meaning of the present invention may be administered by means of (dispensed from) syringes under normal conditions under normal pressure.
  • the filler composition of the present invention is preferably (essentially) sterile.
  • the injectable composition is suitable for injection into a mammal, in particular a human.
  • Re-shaping may be performed for cosmetic purposes or may be performed after loss of tissue such as, e.g., caused by an accident or by a surgical intervention. For instance, a part of the face may be injured by an accident. On the other hand, cheekbones may be accentuated by filling the cheekbone region subcutaneously. A breast or part thereof may be surgically removed. On the other hand, breast reconstruction or augmentation may also have aesthetic reasons.
  • the injectable composition of the present invention may be administered in an effective amount to an individual by injection, such as by subcutaneous or intradermal injection.
  • the injectable composition is a filler.
  • the injectable composition is a filler, in particular a super-volumizer, and the use comprises the administration of the composition comprising the cross-linked material of the present invention in the tissue of interest, in particular subcutaneously or intradermally.
  • the injectable composition may be intradermally or subcutaneously injected using the serial puncture technique.
  • An effective amount refers to the amount of the (injectable) soft tissue filler composition sufficient to effect beneficial or desired cosmetic (aesthetic) or therapeutic results.
  • the injectable composition is a filler which may be a super-volumizer, in particular a soft tissue filler, and the use comprises administration of the composition comprising the crosslinked material of the present invention subcutaneously or intradermally.
  • the cross-linked material according to the present invention is particularly beneficial because the cross-linked material rather stable in aqueous environments such as body fluids and enables invasion of cells due to its structure and characteristics.
  • a further aspect of the present invention relates to the cross-linked material or the injectable composition according to the present invention for use in a method for regenerating tissue of an individual in need thereof.
  • the present invention also relates to a method for regenerating tissue of an individual in need thereof, said method comprising administration of the crosslinked material or the injectable composition according to the present invention to the individual in need thereof.
  • Regenerating tissue of an individual in need thereof may be performed for therapeutic and/or cosmetic purposes. It will be understood that the definitions and preferred embodiments as laid out in the context of the cross-linked material, the hydrogel, the methods and the injectable composition above mutatis mutandis apply to the use of regenerating tissue of an individual.
  • the tissue to be regenerated may be any tissue.
  • the tissue is a soft tissue.
  • the tissue is a soft tissue selected from the group consisting of dermal tissue (including tissue of the dermis and the subcutis) and connective tissue.
  • the method may be used for reshaping and rejuvenation, including the uses as described above.
  • the tissue is an articulation (joint) tissue.
  • the cross-linked material may comprise one or more cell proliferation factors stimulating proliferation of the respective tissue.
  • the tissue is bone tissue.
  • the crosslinked material of the present invention may be administered in a location where bone tissue is intended to grow such as e.g., in a gap of a bone fracture or for elongation of bones.
  • the cross-linked material may comprise one or more cell proliferation factors stimulating bone cell proliferation.
  • the cross-linked material according to the present invention is particularly beneficial because the cross-linked material is rather stable in aqueous environments such as body fluids and enables invasion of cells due to its cross-linked structure and surface characteristics.
  • the cross-linked material of the present invention is obtained by the inventive material obtained when conjugating polysaccharide moieties.
  • This conjugate as such also bears unexpectedly beneficial properties.
  • the terms “approximately” and “about” may be understood as a scope including a deviation of up +/- 10% of the respective number value. It will be understood that the specific values are also explicitly disclosed. It will be further understood that the scope embraces the number values provided as commonly rounded values that embrace the whole rounding limits. For example, the scope of “1 mg” embraces the range of from 0.50 to 1 .49 mg.
  • Figure 1 shows an example of extrusion force measurements for a hyaluronic acid (HA) product cross-linked with 1.5 eq. of DMTMM. The measurements were performed using TSK 27G 1 ” needle at 12.6 mm/min. The figure shows an overlay of multiple measurements. It is visible that the measurements lead to comparable results and no significant inhomogeneities were found.
  • HA hyaluronic acid
  • Figure 2 shows degradation kinetics of cross-linked materials each based on hyaluronoic acid (HA) which was cross-linked by different contents of DMTMM.
  • the degradation was performed with contacting the respective cross-linked material with 150 units of hyaluronidase and incubation at 37°C.
  • the upper graphs show HA obtained from a first supplier.
  • the lower graphs show HA obtained from another supplier.
  • the triangle pointing downwards indicate non-cross-linked HA.
  • the squares indicate HA cross-linked with 0.5 equivalents (eq.) of DMTMM.
  • the circles indicate HA cross-linked with 1.0 eq. of DMTMM.
  • the triangle pointing upwards indicate HA cross-linked with 1 .5 eq. of DMTMM.
  • the 45 mL of PBS buffer containing (HA) and the 5 mL of PBS buffer containing DMTMM were mixed with each other. This achieves a HA concentration of 30 mg/mL. Mixing was conducted until a visually homogeneous composition was achieved. This was typically achieved after approximately 10 min.
  • the cross-linked material (present as a hydrogel) was homogenized once more for 30 min and passed through a sieve (screening). This was noted to be an optional step that could also be omitted.
  • the cross-linked material (present as a hydrogel) was placed in dialysis membranes (molecular weight cut-off (MWCO) 12-14 kDa) and was purified for approximately 2 days to remove the side products of the DMTMM.
  • the swelling ratio was controlled by the weight of the membranes and the dialysis stopped once the product showed the desired cross-linked material concentration. This was noted to be an optional step that could also be omitted.
  • a local anesthetic such as lidocaine is added to the cross-linked material (present as a hydrogel).
  • the cross-linked material (present as a hydrogel) is subjected to sterilization and optionally filled in syringes.
  • Rheology (including intrinsic viscosity) was determined using a 302 Modular Compact Rheometer (Anton Paar GmbH, Graz, Austria). Briefly, plate/plate in oscillation mode (PP20) with a 1 .0 mm gap size at 25°C was used; Tau (stress) was set to 10 Pa, and the oscillation frequency ranged from 10 to 0.1 Hz. Reported G' values correspond to 1 Hz.
  • Extrusion force was measured using a TA.XT.(Stable Micro Systems) Plus texture analyzer. Briefly, syringes were extruded at constant speed (12.6 mm/min), and the forces (in N) were measured over time. A ->2inch 27G TSK (TSK Laboratory, Japan) needle,
  • Enzymatic Degradation The material degradation was evaluated though Rheometer Anton Paar MCR 302, plate CP50-1 at 36°C in the oscillation modus. The measurement points were recorded each minute for 1 hour. The content of one syringe (1 mL) was deposited on the measuring plate and 150 pL of hyaluronidase solution with 150 U (activity units) was mixed in the gel for 30 seconds. The G’ values at 1 Hz were converted in degradation % to report the values.
  • Example 2 In the same manner as for Example 1 , 2.0 g of chondroitin sulphate (CS) with a weight average molecular weight of 100 kDa was solubilized in PBS buffer (pH 7.4). Different contents (approximately 0.0, 0.5, 1 .0 or 1 .5 molar equivalents (eq.) related to the carboxyl groups of CS) of DMTMM were dissolved in PBS buffer of pH 7.4 and mixed with the PBS buffer containing CS, until a visually homogeneous composition was achieved, and the mixture was allowed to react at 23 °C for 17 h. Subsequently, the crosslinked hydrogel was purified by dialysis using PBS buffer.
  • PBS buffer pH 7.4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La présente invention concerne un procédé de préparation d'un matériau réticulé, comprenant la réaction d'au moins certains résidus d'acide carboxylique de fractions polysaccharidiques avec au moins certains résidus hydroxy de fractions polysaccharidiques pour former des liaisons ester réticulant des fractions polysaccharidiques de manière covalente les unes avec les autres, la réaction étant déclenchée par un ou plusieurs agents d'activation à base de triazine. En outre, l'invention concerne un matériau réticulé pouvant être obtenu à partir d'un tel procédé, des compositions comprenant de tels matériaux, et leurs utilisations.
PCT/EP2024/064195 2023-05-25 2024-05-23 Matériau réticulé comprenant des fractions polysaccharidiques interconnectées par des liaisons ester Pending WO2024240864A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024277576A AU2024277576A1 (en) 2023-05-25 2024-05-23 Cross-linked material comprising polysaccharide moieties interconnected by ester bonds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23175399.7 2023-05-25
EP23175399 2023-05-25

Publications (1)

Publication Number Publication Date
WO2024240864A1 true WO2024240864A1 (fr) 2024-11-28

Family

ID=86605053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/064195 Pending WO2024240864A1 (fr) 2023-05-25 2024-05-23 Matériau réticulé comprenant des fractions polysaccharidiques interconnectées par des liaisons ester

Country Status (4)

Country Link
AR (1) AR132765A1 (fr)
AU (1) AU2024277576A1 (fr)
TW (1) TW202513100A (fr)
WO (1) WO2024240864A1 (fr)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341745A1 (fr) 1988-05-13 1989-11-15 FIDIA S.p.A. Polysaccharides carboxylés réticulés
JP2003252905A (ja) 2002-02-28 2003-09-10 Denki Kagaku Kogyo Kk 架橋ヒアルロン酸
WO2011119468A1 (fr) 2010-03-22 2011-09-29 Allergan, Inc. Hydrogels réticulés à base de polysaccharides et de protéines- polysaccharides pour l'augmentation des tissus mous
US20120190644A1 (en) 2009-08-27 2012-07-26 Fidia Farmaceutici S.P.A. Viscoelastic gels as novel fillers
WO2015149941A1 (fr) 2014-04-01 2015-10-08 Merz Pharma Gmbh & Co. Kgaa Produits de comblement de tissu mou à base de polysaccharide, à persistance améliorée
CN105713211A (zh) 2014-12-02 2016-06-29 上海其胜生物制剂有限公司 一种新型皮肤填充剂的制备方法
EP3252082A1 (fr) * 2016-05-31 2017-12-06 Galderma S.A. Procédé pour la désacétylation de biopolymères
WO2019002369A1 (fr) 2017-06-28 2019-01-03 Nestlé Skin Health Sa Hydrogel de glycosaminoglycane avec dextrane ou cyclodextrine greffé
JP2019019201A (ja) 2017-07-14 2019-02-07 キユーピー株式会社 架橋ヒアルロン酸、及びその製造方法
WO2020030629A1 (fr) 2018-08-07 2020-02-13 Merz Pharma Gmbh & Co. Kgaa Procédé de filtration dynamique d'un hydrogel réticulé
US20200140626A1 (en) 2017-06-28 2020-05-07 Nestlé Skin Health S.A. Method of preparing a hydrogel product
WO2022268871A1 (fr) 2021-06-23 2022-12-29 Merz Pharma Gmbh & Co. Kgaa Réticulation d'un polysaccharide avec de la fibroïne et utilisations du matériau obtenu

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341745A1 (fr) 1988-05-13 1989-11-15 FIDIA S.p.A. Polysaccharides carboxylés réticulés
JP2003252905A (ja) 2002-02-28 2003-09-10 Denki Kagaku Kogyo Kk 架橋ヒアルロン酸
US20120190644A1 (en) 2009-08-27 2012-07-26 Fidia Farmaceutici S.P.A. Viscoelastic gels as novel fillers
WO2011119468A1 (fr) 2010-03-22 2011-09-29 Allergan, Inc. Hydrogels réticulés à base de polysaccharides et de protéines- polysaccharides pour l'augmentation des tissus mous
WO2015149941A1 (fr) 2014-04-01 2015-10-08 Merz Pharma Gmbh & Co. Kgaa Produits de comblement de tissu mou à base de polysaccharide, à persistance améliorée
CN105713211A (zh) 2014-12-02 2016-06-29 上海其胜生物制剂有限公司 一种新型皮肤填充剂的制备方法
EP3252082A1 (fr) * 2016-05-31 2017-12-06 Galderma S.A. Procédé pour la désacétylation de biopolymères
WO2019002369A1 (fr) 2017-06-28 2019-01-03 Nestlé Skin Health Sa Hydrogel de glycosaminoglycane avec dextrane ou cyclodextrine greffé
US20200140626A1 (en) 2017-06-28 2020-05-07 Nestlé Skin Health S.A. Method of preparing a hydrogel product
JP2019019201A (ja) 2017-07-14 2019-02-07 キユーピー株式会社 架橋ヒアルロン酸、及びその製造方法
WO2020030629A1 (fr) 2018-08-07 2020-02-13 Merz Pharma Gmbh & Co. Kgaa Procédé de filtration dynamique d'un hydrogel réticulé
WO2022268871A1 (fr) 2021-06-23 2022-12-29 Merz Pharma Gmbh & Co. Kgaa Réticulation d'un polysaccharide avec de la fibroïne et utilisations du matériau obtenu

Also Published As

Publication number Publication date
TW202513100A (zh) 2025-04-01
AR132765A1 (es) 2025-07-30
AU2024277576A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
AU2016338072B2 (en) In situ cross-linkable polysaccharide compositions and uses thereof
EP3538066B1 (fr) Compositions de comblement dermique comprenant de l'acide hyaluronique réticulé avec l'acide citrique. procédé de fabrication de celui-ci et utilisation de celui-ci
KR101672562B1 (ko) 마취제를 포함하는 히알루론산-기반 젤
KR102154944B1 (ko) 항산화제를 포함하는 피부 충전제 조성물
EP2550027B1 (fr) Hydrogels réticulés à base de polysaccharides et de protéines- polysaccharides pour l'augmentation des tissus mous
CA2919792C (fr) Composition comportant de l'acide hyaluronique et la mepivacaine
US20220062151A1 (en) Aldehyde-modified hyaluronic acid, method for preparing same and applications thereof
WO2014055895A1 (fr) Dispositif injectable et méthode de modelage, d'augmentation ou de correction de traits faciaux tels que du menton
US20140039062A1 (en) Injectable device and method for sculpting, augmenting or correcting facial features such as the chin
US20190269582A1 (en) Method for preparing hyaluronic acid dermal fillers, dermal fillers obtained thereby and their use
US20240317900A1 (en) Cross-linking polysaccharide with fibroin and uses of the obtained material
US20250255798A1 (en) Hydrogels for soft tissue filling
WO2024240864A1 (fr) Matériau réticulé comprenant des fractions polysaccharidiques interconnectées par des liaisons ester
US20240307590A1 (en) Hyaluronic acid dermal fillers crosslinked with polyethylene glycol diglycidyl ether, method for making same and uses thereof
WO2025088047A1 (fr) Formulations d'implant dermique
HK40029946A (en) Hyaluronic acid-based gels including anesthetic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24728981

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2024277576

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2024277576

Country of ref document: AU

Date of ref document: 20240523

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: CN2024800351758

Country of ref document: CN

Ref document number: 2501008039

Country of ref document: TH

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025025851

Country of ref document: BR